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DISCOVERY OF PYRAZOLOPYRIDINE DERIVATIVES DUALLY TARGETING 
INFLAMMATION AND PROLIFERATION IN COLORECTAL CANCER CELL LINES: IN-
SILICO DRUG DESIGN APPROACH 
Abstract 
Elimination of inflammation represents a promising strategy for cancer prevention and treatment since 
cancer and inflammation are related. The combined use of anti-inflammatory agents and cancer therapy 
is a focal point. In this frame, pyrazolopyridine derivatives DZ-BAU2021-6 and DZ-BAU2021-14, developed 
in BAU Labs, having promising anti-proliferative activity on colon cancer cells HCT-116 and HT-29 with 
notable IC50 values and remarkable CDK2 inhibitory effect, were in-silico tested. As an approach to dual 
anti-inflammatory anticancer potential, their binding modes and energies on the active site of crystalline 
structure of CDK2 and COX2, (1HCK and 3LN1), respectively were explored. Their physicochemical and 
pharmacokinetic properties as well as their “drug-likeness” were studied. Computational results declared 
that DZ-BAU2021-6 and DZ-BAU2021-14 exhibited high binding affinities to CDK2 and COX2 receptors. 
DZ-BAU2021-14 exhibited lower levels of estimated binding energies with COX2 receptor compared to 
Celecoxib. It demonstrated high GI absorption, low interference with P-glycoprotein and cytochrome P450 
isoforms. 
Keywords 
In-silico drug design, colorectal cancer, anti-inflammatory, antiproliferative 





Cancer is a major public health problem and the second leading cause of death worldwide after 
cardiovascular diseases. Cancer is a group of malignant neoplasms that can affect any part of the 
body; its liability is rising globally with an estimated 18 million new cases and 10 million deaths 
every year. Cancer incidence is rapidly rising in all countries, and projected to increase to 30 million 
by 2040 (World Health Organization, 2019). There are still too many cancer affected deaths that can 
be prevented by early diagnosis and effective treatment (Shamseddine et al., 2014). Colorectal cancer 
(CRC) is the fourth world's deadly cancer showing more than 900,000 deaths yearly (Siegel et al., 
2019). 
Protein kinases represent a large family of enzymes essential for the regulation of diverse cell 
functions through phosphorylation of structural proteins and enzymes regulating cell division. Cyclin-
dependent kinases (CDKs) are members of serine/threonine protein kinase family that have been 
implicated as contributing factor in cancer development. Cell cycle progression is mainly controlled 
by CDKs, which successively act in G1 to initiate S phase and in G2 to initiate Mitosis (Whittaker et 
al., 2017). CDKs phosphorylate cellular substrates required for progression into different cell cycle 
phases (Swaffer et al., 2016). Therefore, CDKs are key enzymes in cell cycle control; they are 
promising targets for design and discovery of antiproliferative drugs. The majority of CDK inhibitors 
are competitive that can bind to ATP pocket and inhibit CDKs activity (Martin MP, 2012). Cyclin 
dependent kinase 2 (CDK2), belonging to kinase group, acts as a mediator for cell progression from 
G1 to S phases in association with cyclin A and E. In this respect, CDK2 has been actively regarded 
as a promising drug target for anticancer therapies (Tarfah Al-Warhi, 2020). Great majority of 
clinically used CDK2 inhibitors, although acting by ATP-competition, their structures are quite 
diverse and they are generally comprising or derived from various heterocyclic families such as 
purines namely Roscovitine and Olomoucine, pyrimidines and indoles as in case of Meridianin, as 
well as pyrazoles and thiazoles for Crisotinib and Dasatinib (Bailon-Moscoso et al., 2017; Kim et al., 
2020; Kolodziej et al., 2015; Wu & Fu, 2018). CDk2 expression was proven remarkably upregulated 
in colorectum tumorigenesis. Its overexpression promotes the progression of early cancer and 
correlates with prognosis in colorectal carcinoma (Li et al., 2001; Yamamoto et al., 1998). 
Roscovitine, the potent CDK2 inhibitor, succeeded to treat different cancer types, either as single 
therapy or in combination with other agents. It has a noticeable antiproliferative effect on colon cancer 
cells HCT-116, HT-29 and other cell lines.  Orally administered, Roscovitine caused a reduction in 
tumor growth in HCT-116 and HT-29 human colon cancer xenograft model in nude mice of 79% and 
80% respectively (Cicenas et al., 2015).  
Cancer development is a multi-step process promoted by exposure to chemical irritants or 
inflammatory mediators that induce cell proliferation (O'Neill et al., 2018). Cancer and inflammation 
are related to each other, where great correlation between formation of precancerous lesions and 
inflammation were observed (Matkowskyj et al., 2013). Many reports related overexpression of 
different inflammatory mediators in chronic inflammation to cancer risk, increased cell proliferation, 
metastasis and angiogenesis. Therefore targeting inflammation could develop good strategy for 
cancer therapy and prevention since many epidemiological studies have demonstrated that 
inflammation can predispose to tumors (Silvia Zappavigna & Caraglia, 2020). Many reviews traced 
cyclooxygenase-2 (COX2), studied the overexpression of its biological products prostaglandin E2 
and COX2 mediated factor IL-11 and described their role in regulating angiogenesis, tumorigenesis 
and metastasis (Howe, 2007; Singh-Ranger et al., 2008; Singh et al., 2006). In parallel, clinical studies 
have indicated that long term use of nonsteroidal anti-inflammatory drugs (NSAIDs) decreased the 
incidence of cancer and were believed to play a role in cancer prevention and treatment (Rayburn et 
al., 2009; Thun et al., 2002; Wong, 2019). 
Sheng et al. described specifically the role of COX2 and related mediators in colorectal 
carcinogenesis (Sheng et al., 2020). COX2 signaling and promotion of pathogenesis, angiogenesis 
and metastasis of colorectal cancer were comprehensively detailed in near literature (Liu et al., 2017; 
Masferrer et al., 2000; Zhou et al., 2017). Numerous epidemiologic studies have found that long-term 
users of NSAIDs have a lower risk of colorectal adenomatous polyps and colorectal cancer than 
nonusers (Grau et al., 2009; Mayor, 2015; S. Friis, 2015). NSAIDs whether non-selective or selective 
COX2 inhibitors were proven curative for some adenomatous colorectal cancer stages where Sulindac 
and Celecoxib have been described in a randomized clinical study to reduce the number of polyps 
and their size up to 65%. The uses of COX inhibitors for treatment of colorectal cancer have been 
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raised since colorectal tumor tissue showed higher concentration of prostaglandin E2 than in 
surrounding normal mucosa, randomized clinical trials have confirmed that the prodrug Sulindac and 
the selective COX2 inhibitor Celecoxib inhibited the growth of adenomatous polyps in colorectal 
cancer (Kemp Bohan et al., 2020; Sheng et al., 2020; Steinbach G & Med, 2000). Combining 
Celecoxib and Cetuximab improved the antiproliferative activity by 50% in cetuximab resistant colon 
HT-29 cells (Valverde et al., 2017). 
Colorectal cancer, that still needs proper and effective treatment, represents a therapeutic target 
for drug discovery and development. Co-administration of combined anti-inflammatory anticancer 
treatments might be a respectable approach nevertheless their metabolic and excretory burden. 
Having acknowledged antiproliferative effect on colon cancer cells HCT-116 and HT-29, the purine 
CDK2 inhibitor, Roscovitine was adopted as a lead compound, and directed researchers in the current 
work to select isosteric pyrazolopyridine congeners DZ-BAU2021-6 and DZ-BAU2021-14 for 
further study. The chosen compounds for investigation are reported to have promising CDK2 
inhibitory effect and encouraging antiproliferative activity on colon cancer cells HCT-116 and HT-
29 (Kassem et al., 2021). DZ-BAU2021-6 and DZ-BAU2021-14 comprise fused pyrazolo core which 
is pharmacophoric for COX2 inhibition. The previous stated facts directed the research group to 
explore the anti-inflammatory potential of DZ-BAU2021-6 and DZ-BAU2021-14. This might 
promote the discovery of individual inhibitors possessing both CDK2 and COX2 activities which 
adds highlights towards a twin scope activity saving pharmacokinetic burden of combination 
treatment.  
 
2. MATERIAL AND METHODS 
2.1. Molecular Docking Studies 
In-silico pharmacodynamic studies of DZ-BAU2021-6 and DZ-BAU2021-14 1  were 
carried out to gain a perception of their binding forces and energies to the active sites of target 
proteins. Mol files of docked compounds were generated by drawing their structures using 
ChemSketch (ACD\Labs Chemistry Software) and transformed into PDB format via Open Babel 
(O'Boyle et al., 2011). The PDB files of X-ray crystal structures of selected receptors CDK2 
(PDB ID: 1HCK) (Schulze-Gahmen et al., 1996) and COX2 (PDB ID: 3ln1) (Wang et al., 2010) 
were retrieved from the online protein database (Berman et al., 2000; RCSB-Protein Data Bank). 
The crystal structure of target protein 1HCK was treated by removing the co-crystallized ligand 
ATP, water and magnesium. Similarly, 3ln1 was freed from Celecoxib and water molecules. 
Optimization and energy minimization were achieved using Swiss PDB viewer V.4.1.0 software 
(Johansson et al., 2012). AutoDock4.0 software was used to perform Molecular docking based 
on Lamarckian Genetic Algorithm (Morris et al., 2009). Polar hydrogens addition to protein and 
Kollman united atomic charges were computed using AutoDock hydrogen module. Using Auto 
Grid function, grid maps were calculated, Grid size was set to 40*40*40 points and grid spacing 
of 0.375 Å. Grid box was assigned to include the active residue in center. Default docking 
algorithms were specified in agreement with standard docking protocol. Ten runs were executed 
for each ligand using Cygwin (Cygwin project). Lowest binding energies were clustered 
according to 1.0 Å RMSD tolerance criteria and estimated inhibition constant Ki and docking 
energies were calculated. UCSF Chimera was used for H-bond analysis (Pettersen et al., 2004).  
MOE2014.0901 (MOE, 2014) was used to analyze pi bonds, lipophilic, hydrogen donor-
acceptor interactions and Van der Waals forces of attraction with different amino acids.  
 
2.2. Validation of Molecular Docking 
Validation of prepared protein receptor models 1HCK and 3LN1 was achieved by 
experimental docking of ATP and Celecoxib to their binding sites respectively. They exhibited 





                                                          
1 Two derivatives developed in Faculty of Pharmacy - Beirut Arab University, as apart of pharmacist Zahra 
Kassem PhD thesis. 
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2.3. Pharmacokinetic in-Silico Studies 
The 2D chemical structures were drawn on Swiss ADME submission page (Swiss Institute 
of Bioinformatics, 2021). Computation of physicochemical properties and drug-likeness was 
appraised and displayed as Bioavailability Radar. Binding to permeability glycoprotein (P-gp) 
and inhibiting cytochrome P450 (CYP) isoforms were estimated by applying support vector 
machine algorithm (SVM). Gastrointestinal (GI) absorption and blood brain barrier (BBB) 
penetration was predicted by boiled-egg model. The bioavailability is calculated according to 
Abbott score (Martin, 2005). 
 
3. DISCUSSION AND RESULTS 
3.1. Prediction of Pharmacodynamic Properties 
In this study, aiming at discovering new derivatives having twin effect as anti-
inflammatory and CDK2 suppressor effectiveness, the hopeful anti COX2 activity of DZ-
BAU2021-6 and DZ-BAU2021-14 was in-silico studied. The current work examines the 
anticipated mode of receptor interaction of the novel CDK2 inhibitors, DZ-BAU2021-6 and DZ-
BAU2021-14, on both CDK2 and COX2 receptor active sites and explores their hypothetical 
binding affinities. In this respect DZ-BAU2021-6 and DZ-BAU2021-14 were docked to the 
active site of 1HCK and 3ln1. 
 
3.1.1. Binding mode of study compounds at cdk2 active site 
To gain a perception of the binding mode of ATP with CDK2 and exploring the 
protein-ligand pocket environment, their co-crystallized structure, 1HCK, was observed. 
Analyzing the ATP pocket of 1HCK, as seen in PDB, it showed hydrogen bonds at the 
level of Asn132, Asp145, Gln131, Glu81, Gly13, Leu83, Lys33, Lys129 and Thr14. 
Purine nucleus was hosted by the hydrophobic parts of Ile10, Leu83, Leu134 and Val18 
(Fig. 1).  
 
Fig.1: 2D view of ATP interaction with CDK2 (pdb entry: 1HCK) (Protein Data Bank in 
Europe; Schulze-Gahmen et al., 1996) 
 
Molecular docking of pyrazolopyridine derivatives, and Roscovitine was carried 
out against the treated 1HCK active binding site. ATP was redocked for validation, where 
it demonstrated similar ligand-receptor adaptive fitting involving same amino acid 
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residue interactions. The estimated docking energies and 3D interaction models are 
illustrated in Table 1 and Fig. 2-5. 
 
              Table 1: Ligand-protein docking energies in kcal/mol at the active site of 1HCK 
 
Compound 
Estimated    
Free       










VdW     
+Hbond            
+desolv.      
Energy   
Electro-      
static       
Energy  
Final           
Total      
Internal  
Energy  
Torsional    













-8.84 0.33 -10.12 -9.88 -0.24 -0.79 +1.19 -0.87 
ATP -6.21 28.25 -10.70 -9.09 -1.61 -5.46 +4.18 -5.77 
Roscovitine -7.88 1.68 -9.58 -9.15 -0.43 -1.65 +2.68 -0.66 
a Estimated Inhibition Constant, Ki is characterized in Micro-molar concentration at Temperature = 298.15 K. 
 
The estimated ligand-receptor free binding energy, upon redocking of ATP, was -
6.21 kcal/mol (table 1). At its docking active site against prepared 1HCK, at the level of 
ribose, ATP exhibited three H-bond donors with the side chain of Asp145 of 2.57, 2.95 
and 3.20 Å, four H-bond acceptors of 2.74, 3.08, 3.17 and 3.59 Å bond distances with 
amino group of Lys33. The phosphate residue dominated many hydrogen bonds; three 
H-bond acceptors with Lys129 and three H-bonds involving the hydroxyl group of Thr14, 
the carboxamide side chain of Asn132 and the back bone of Gly13 of 2.72, 3.00 and 3.14 
Å respectively. Purine and ribose skeleton were hosted by the hydrophobic region formed 
by Gln131, Gly13, Leu83, Leu134, Ile10, Lys129 and Val18 (Fig. 2).  
 
Fig.2: 3D interaction model of ATP with CDK2 kinase (1HCK) upon redocking 
 
DZ-BAU2021-6 revealed estimated free binding energy of -7.35 kcal/mol (table 
1). Its 3D interaction binding model with CDK2 kinase (1HCK) illustrated two H-bond 
acceptors at the level of pyrazolo N6 and pyridino N7 with amino group of Lys33 of 3.68 
and 2.83 A˚ respectively. The carbon skeleton was seen lodged in the lipophilic pocket 
formed by non-polar residues of Ileu10, Leu134 and Val18, with non-coplanar Van der 
Walls forces of attraction involving benzene rings of Phe80 and Phe82 (Fig. 3).  
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       Fig.3: 3D interaction model of DZ-BAU2021-6 with CDK2 kinase (1HCK) 
 
Compound DZ-BAU2021-14 showed estimated free binding energy of -8.84 
kcal/mol (table 1). It displayed many H-bond interactions with various amino acid 
residues at the active pocket of CDK2 kinase (1HCK); triazino N1 and N2 were 
stabilized as two H-bond acceptors with Lys33 amino group of 2.98 and 2.75 Å 
respectively. Two H-bond acceptors were depicted between the ligand ethanoate 
carbonyl and NH groups of Lys129 and Thr14 with a bond distance 3.29 and 3.22 Å 
respectively. In addition, the ethanoate oxygen was involved in H-bond acceptor of 3.18 
Å length with NH group of Tyr15 while the methyl group elaborated a H-bond donor 
3.14 Å with carbonyl side chain of Asp86. The exposed skeleton was accommodated in 




Fig.4: 3D interaction model of DZ-BAU2021-14 with CDK2 kinase (1HCK) 
 
Docking of Roscovitine to CDK2 active pocket depicted a binding energy of -
7.88 kcal/mol (table 1). Ligand-receptor interaction displayed H-bond acceptor of 3.21 
Å between purine N3 and amino group of Lys33. In addition, butanol amino NH 
established a H-bond donor of 3.11 Å with the carbonyl side chain of Asp86. The 
hydroxyl group showed H-bond acceptor of 3.18 Å with amino group of Lys89 and H-
bond donor of 2.67 Å with carbonyl side chain of Asp86. The carbon chains were 
interacting hydrophobically with Gln131, Ile10 and Leu134 (Fig. 5). 
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                     Fig.5:  3D interaction model of Roscovitine with CDK2 kinase (1HCK) 
 
Both compounds DZ-BAU2021-6 and DZ-BAU2021-14 showed low levels of 
estimated binding energies. DZ-BAU2021-14 illustrated the lowest binding energies 
and the lowest estimated inhibition constant. It exhibited better binding criteria than 
Roscovitine; -8.84, -10.12, and -9.88 Kcal/mol compared to -7.88, -9.58 and -9.15 
Kcal/mol assigned to estimated free binding energy, final intermolecular energy and 
total sum of Van der Walls + hydrogen bonding + desolvation energy, respectively. DZ-
BAU2021-14 demonstrated one-fourth the estimated inhibition constant (Ki) of 
Roscovitine (0.33 to 1.68 µM). The endogenous substrate ATP exhibited the best final 
intermolecular energy (table 1). The final intermolecular energy value -10.12 Kcal/mol 
assigned for DZ-BAU2021-14 compared to -1.70 Kcal/mol for ATP indicates the 
stability of DZ-BAU2021-14 in its ligand-receptor complex pocket.  
 
3.1.2. Binding Mode of Study Compounds at COX2 Active Site 
The anti-inflammatory effect of DZ-BAU2021-6 and DZ-BAU2021-14 was tested 
by inspecting their COX2 inhibitory activity in-silico; the anticipated binding interactions 
and affinities to COX2 receptor were studied by docking them to the active site of COX2 
using the prepared crystalline protein structure 3ln1. In parallel, the binding mode of 
Celecoxib to COX2 receptor was explored to recognize the assembly of amino acids-
ligand setting.  
The crystalline structure 3ln1 depicted the interaction of the embedded celecoxib 
through H-bonds at the level of Arg499, Gln178, His75, Leu338, Phe504 and Val50 as 
well as an assembly of pi-C, pi-H and hydrophobic interactions with Ala513, Gln178, 
Gly513, Leu338, Phe504, Ser339, Tyr341, Val335 and Val509. Trifluoromethyl group 
was logged in the lipophilic pocket created by Leu517, Tyr341 and Val335 (Fig. 6). 
 
 
Fig.6: 2D view of Celecoxib interaction with COX2 (pdb entry: 3LN1) (Protein Data Bank in 
Europe; Wang et al., 2010) 
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Molecular docking of DZ-BAU2021-6 and DZ-BAU2021-14 was carried out 
against the treated 3ln1 active binding site. Celecoxib was redocked for validation, it 
proved analogous ligand-receptor interactions compared to the untreated 3ln1 
crystallized ones, involving same amino acid residues. The estimated docking energies 
and 3D interaction models are demonstrated in Table 2 and Fig. 7-9. 
 
Table 2. Ligand-protein docking energies in kcal/mol at the active site of 3ln1 
 
Compound 
Estimated    
Free       










VdW     
+Hbond            
+desolv.      
Energy   
Electro-      
static       
Energy  
Final           
Total      
Internal  
Energy  
Torsional    












-9.66 0.08 -10.80 -10.63 -0.17 -0.93 +1.19 -0.87 
Celecoxib -9.47 0.11 -10.38 -10.36 -0.02 -0.13 +0.89 -0.14 
                   a Estimated Inhibition Constant, Ki is characterized in Micro-molar concentration at Temperature = 298.15 K. 
 
DZ-BAU2021-6 showed low estimated free binding energy of -7.50 Kcal/mol. In 
its 3D interaction model with COX2 crystallized structure (3ln1), it displayed a H-bond 
donor of 3.62 Å length between methyl group and carbonyl side chain of Gln178 while 
the exposed groups underwent hydrophobic contacts with Ala513, Leu338, Tyr341, 
Val509 and Val335 (Fig. 7).  
 
 
Fig.7: 3D interaction model of DZ-BAU2021-6 with COX-2 (3ln1) 
 
DZ-BAU2021-14 demonstrated estimated free binding energy of -9.66 Kcal/mol. 
Its binding interaction against COX2 crystallized structure (3ln1) displayed many H-
bonds with different amino acid residues. Triazino methyl and ethanoate methylene 
groups were stabilized by establishing H-bond donors with carbonyl side chain of Gln178 
and carbonyl backbone of Leu338 with bond lengths 3.79 and 3.04 Å respectively. The 
ethanoate carbonyl group exhibited a H-bond acceptor of 3.14 Å with the basic amino 
acid Arg499. In addition, the triazino ring interacted with Val509 through two pi–H 
bonds of 3.63 and 3.91 Å respectively. The exposed carbon skeleton was lodged in the 
hydrophobic pocket formed by six amino acid residues Ala513, Leu338, Ser339, Tyr341, 
Val335 and Val509 (Fig. 8). 
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Fig.8: 3D interaction model of DZ-BAU2021-14 with COX-2 (3ln1) 
 
Upon redocking of Celecoxib in its target binding site of COX2 crystallized 
structure (3ln1), it showed estimated free binding energy of -9.47 Kcal/mol. Celecoxib 
amino group was stabilized by establishing two interactions; H-bond donor with back 
bone carbonyl of Val102 of 3.09 Å and H-bond acceptor with side chain NH of Arg106 
of 2.69 Å. A pi-H bond of 3.96 Å length was depicted between the methyl substituted 
phenyl and Val509. The exposed carbon backbone was hosted by the hydrophobic parts 
of Ala513, Leu338, Leu517, Phe504, Ser339, Tyr341, Val335 and Val509 (Fig. 9).   
           
 
   Fig.9: 3D interaction model of Celecoxib with COX-2 (3ln1) upon redocking 
 
The binding modes attributed to Celecoxib (Dhanjal et al., 2015), Valdecoxcib (Di 
Fiore et al., 2006) and Rofecoxcib (Orlando & Malkowski, 2016) with COX2 receptor 
were quite similar. They pointed a particular active pocket and same amino acid residues 
that are shared with the study compounds DZ-BAU2021-6 and DZ-BAU2021-14. This 
raised the presumption hits of their anti-inflammatory activity. 
Estimated binding energies for DZ-BAU2021-6 and DZ-BAU2021-14 indicated 
binding affinities to COX2 receptor (3ln1) (table 2). According to the obtained values 
DZ-BAU2021-14 showed the lowest binding energies and estimated inhibition constant 
(Ki). Compared to Celecoxib, DZ-BAU2021-14 showed -9.66, -10.80 and -10.63 
Kcal/mol to -9.47, -10.38 and -10.36 Kcal/mol for Celecoxib specifying their estimated 
free binding energy, final intermolecular energy and total sum of Van der Walls + 
hydrogen bonding + desolvation energy, respectively. DZ-BAU2021-14 demonstrated 
three-fourth the estimated inhibition constant (Ki) of Celecoxib (0.08 to 0.11µM). From 
the previous data, DZ-BAU2021-14 revealed superior binding interactions with COX2 
crystalline structure (3ln1) compared to Celecoxib. This can be proved considering not 
only its lower values at the level of binding energies and estimated inhibition constant, 
but also possessing higher number of hydrogen bonding and additional pi-H interactions 
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3.2. Prediction of Pharmacokinetic Properties 
As the penetration of DZ-BAU2021-14 to colorectal cell lines HCT-116 and HT-29 was 
proven by its antiproliferative CDK2 inhibitory activity as concluded from its biological in- vitro 
results (Kassem et al., 2021), tracing its physicochemical and pharmacokinetic properties is 
fundamental to develop an idea about its bioavailability and different tissue concentration. In 
this respect Swiss ADME web tool (Daina et al., 2017; Swiss Institute of Bioinformatics, 2021) 
was used to evaluate the pharmacokinetics and drug-likeness of DZ-BAU2021-6 and DZ-
BAU2021-14. 
From the first glance the Bioavailability Radar presentation of compound DZ-BAU2021-
6 reflected high lipophilicity and low polarity levels with notably limited flexibility and high 
unsaturation level (Fig.10). The estimated n-octanol/water partition coefficients expressed as 
Log Po/w demonstrated a range of values between 2.94-3.87 with a consensus Log Po/w of 3.60 
predicting high lipophilicity. Water solubility was read as poor to moderate. Compound DZ-
BAU2021-6 exhibited a high estimated GI absorption, BBB penetration. It was detected as a 
substrate for permeability glycoprotein (P-gp) and showed inhibitory potential to CYP1A2, 
CYP2C19, CYP2C9 and CYP3A4 while it had no effect on CYP2D6. Swiss ADME described 
compound DZ-BAU2021-6 as a drug-like having bioavailability score of 0.55. No violation was 
depicted.    
Compared to DZ-BAU2021-6, compound DZ-BAU2021-14 showed in its Bioavailability 
Radar presentation slight lower lipophilicity and less polarity. Higher flexibility and saturation 
levels were observed (Fig. 10). Compound DZ-BAU2021-14 exhibited lower order of 
lipophilicity; its estimated n-octanol/water partition coefficients were ranging between 2.90-3.43 
with a consensus Log Po/w value of 3.16, anticipating optimum lipophilic behavior with poor to 
moderate water solubility scores. The predicted pharmacokinetic properties illustrated high GI 
absorption, and no BBB penetration. It was not assigned as a P-gp substrate which boosts its 
intracellular concentration and limits it efflux. Compound DZ-BAU2021-14 demonstrated 
inhibitory activity for CYP1A2, CYP2C19 and CYP2C9 while it had no effect on CYP2D6 and 



















Fig.10: Bioavailability Radar describing lipophilicity, size, polarity, insolubility, unsaturation and 
flexibility 
                                                                                                       
The estimated high levels of lipophilicity and low levels of polarity and water solubility 
in addition to GI absorption indicated potential oral bioavailability for both candidates DZ-
BAU2021-6 and DZ-BAU2021-14 and postulated them for drug-likeness. Superior pattern was 
observed for DZ-BAU2021-14; it was not determined P-gp substrate which would reflect its 
intracellular concentration. In addition, it revealed lower potential for drug-drug interaction at 
DZ-BAU2021-6 DZ-BAU2021-14 
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the level of CYP inhibition in comparison to DZ-BAU2021-6. Moreover, having no BBB 
penetration, it is hypothesized to grace no central side effect.   
 
4. CONCLUSION  
Understanding the complementary response associated to COX2 and CDK2 inhibition in 
controlling cell proliferation and prognosis of colorectal cancer, the current work affords the 
computational studies of DZ-BAU2021-6 and DZ-BAU2021-14 depicting the superior in-silico 
activity of the CDK2 inhibitor DZ-BAU2021-14 against COX2 receptor model compared to 
Celecoxib. DZ-BAU2021-14 exhibited high GI absorption along with absence of P-gp interference 
and lower CYP interaction which promotes its nomination as an individual candidate assembling 
CDK2-COX2 inhibitory effects against colorectal cancer cells with designated oral activity and low 
drug-drug interaction possibilities. This might inaugurate the discovery of discrete CDK2-COX2 
inhibitors and add exponential highlights towards a dual scope activity saving pharmacokinetic loads 
of individual drug combination. 
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